Izonsteride

From Self-sufficiency
Jump to: navigation, search
Izonsteride
File:Izonsteride-structure.png
Systematic (IUPAC) name
(4aR,10bR)-8-[(4-ethyl-1,3-benzothiazol-2-yl)sulfanyl]-4,10b-dimethyl-1,4,4a,5,6,10b-hexahydrobenzo[f]quinolin-3(2H)-one
Clinical data
Routes of
administration		 Oral
Legal status
Legal status
  • Uncontrolled
Identifiers
CAS Number 176975-26-1
ATC code none
PubChem CID 172988
ChemSpider 151061
Chemical data
Formula C24H26N2OS2
Molar mass 422.61 g/mol[[Script error: No such module "String".]]
Script error: No such module "collapsible list".
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Izonsteride (LY-320,236) is a selective inhibitor of the 5α-redcutase, with dual effects on both the type I and type II isoforms of the enzyme.[1] It was under development by Eli Lilly and Fujisawa for the treatment of benign prostatic hyperplasia (BPH) but was never marketed.[2] Izonsteride may also be useful in the treatment of male pattern baldness (MPB).[1]

See also

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />


5α-reductase inhibitors
Alpha blockers (α1)
Herbals
Other dermatological preparations (D11)
Medicated shampoos
Cetrimide - Cadmium compounds - Selenium compounds - Povidone-iodine - Sulfur compounds - Xenysalate
Other dermatologicals
Other
  1. ↑ 1.0 1.1 Chang, Chawnshang (2002). Androgens and androgen receptor : mechanisms, functions, and clinical application. Boston: Kluwer Academic Publishers. ISBN 1-4020-7188-4. 
  2. ↑ "Present and future pharmacotherapy for benign prostatic hyperplasia". 
Retrieved from "http://ssf.f15ijp.com/wiki/index.php?title=Izonsteride&oldid=23927"